The highest frequency of CDKN2A ALT was observed in patients with esophagogastric cancer, followed by thymic tumor, pancreatic cancer, gallbladder carcinoma and melanoma (Fig. 5E). This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.